Bristol-Myers Squibb completes tender offer for all outstanding shares of Amylin

Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company ("Bristol-Myers Squibb") through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) ("Amylin") at a purchase price of $31.00 per share. As of the expiration of the offer, 140,550,153 shares of common stock of Amylin were validly tendered and not withdrawn in the tender offer. All of such shares have been accepted for payment in accordance with the terms of the tender offer. The tender offer expired at 5:00 p.m., New York City time, on August 7, 2012. As a result of the tender offer, Bristol-Myers Squibb now owns, together with its subsidiaries, approximately 85.55% of the outstanding shares of Amylin.

As part of the successful completion of the tender offer, Bristol-Myers Squibb has exercised its right, granted under the merger agreement with Amylin pursuant to which the tender offer was made, to purchase additional shares from Amylin which will allow Bristol-Myers Squibb to complete and close the merger and acquisition of Amylin today without stockholder approval. Upon completion of the merger, Amylin will become a wholly-owned subsidiary of Bristol-Myers Squibb. All outstanding shares of common stock of Amylin, other than shares held by Bristol-Myers Squibb, B&R Acquisition Company or Amylin in treasury or shares held by Amylin's stockholders who are entitled to and properly exercise appraisal rights under Delaware law, will be canceled and converted into the right to receive cash equal to the $31.00 offer price per share without interest thereon and less any applicable withholding taxes. In addition, upon completion of the merger, the common stock of Amylin will cease to be traded on the NASDAQ Stock Market.